Recent Updates
Recently added Catalysts
ERAS Negative Sentiment Score: 25/100

Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS

Key Takeaway: Erasca Inc. is reminded by ClaimsFiler of the impending deadline for investors to file lead plaintiff applications in a securities class action lawsuit. The lawsuit, pending in the Southern District of California, alleges that Erasca and its executives failed to disclose significant information during the Class Period, which could mislead investors. Specific claims involve the questionable preclinical data associated with ERAS-0015, resulting in potential legal liabilities for the company.

Market Sentiment Analysis

CONCERNS & RISKS

  • Erasca facing a securities class action lawsuit for failing to disclose material information.
  • Investors potentially misled about the preclinical data of ERAS-0015 product.
  • Legal ramifications could negatively impact the company's reputation and share price.

Full Press Release Details

NEW ORLEANS, June 18, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. (NasdaqGS: ERAS) (“Erasca” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Erasca investors should visit us at https://www.claimsfiler.com/cases/nasdaq-eras or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Erasca and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company’s ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lacked a reasonable basis for their positive statements related to ERAS-0015.
The case is Cheng v. Erasca, Inc., No. 26-cv-03481.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline is August 10, 2026.

What period do the securities claims cover?

The claims cover from January 14, 2025, to April 26, 2026.

Where is the lawsuit against Erasca filed?

It is filed in the Southern District of California.

Who should Erasca investors contact for help?

Investors can visit ClaimsFiler or call toll-free at 844-367-9658.

What are the claims against Erasca about?

They involve failing to disclose material information and securities law violations.

Last updated: Jun 18, 2026